Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methylene Blue for the Prevention of Hypotension During Hemodialysis
Sponsor: Federal University of São Paulo
Summary
Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.
Official title: Prospective, Randomized, Controlled Trial Assessing the Effects of Methylene Blue for the Prevention of Hypotension During Renal Replacement Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
261
Start Date
2021-10-21
Completion Date
2025-12-16
Last Updated
2026-04-17
Healthy Volunteers
No
Conditions
Interventions
Methylene Blue
BLUE group will receive an intravenous infusion of methylene blue. Following a previous study(12), 1 mg/kg of methylene blue 2% diluted in 50 mL of saline solution will be administered as a bolus over 5 minutes, followed by a continuous infusion of 0.1 mg/kg body weight in a total of 250 mL of saline solution throughout the RRT session
Control
Usual care during renal replacement therapy
Locations (1)
Federal University of São Paulo
São Paulo, São Paulo, Brazil